Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer

References

• Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer : diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):341s-68s
   Web of Science ®Google Scholar
• Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1S-3S
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:s9-15
   PubMed Web of Science ®Google Scholar
• Houghton AN, Scheinberg DA. Monoclonal antibody therapies a constant threat to cancer. Nat Med 2000;6:373-4
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Ferrara ML, Rossi A. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 2009;14:601-11
   Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus Chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009;373:1525-31
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small cell lung cancer receiving cetuximab in combination with first line chemotherapy: a subgroup analysis of data from the Flex phase III study. Lancet Oncol 2011;12:30-7
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, et al. Cetuximab induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358:1109-17
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28:911-17
   PubMed Web of Science ®Google Scholar
• Thatcher N, Linchy TJ. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials [abstract A3.7]. WCLC 2009;4:S5-968
   Google Scholar
• Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non small cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study. J Clin Oncol 2009;27(Suppl 15):abstract 8007
   Google Scholar
• Schiller JH, von Pawel J, Schutt P, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5:1977-85
   PubMed Web of Science ®Google Scholar
• Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis. Eur J Cancer Suppl 2005;3:abstract 1123
   Google Scholar
• Patel D, Saxena B, Zhou Q, et al. Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR-expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab. Proc Am Soc Clin Oncol 2011;29:abstract e21075
   Google Scholar
• Vera DR, Eigner S, Beran M, et al. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radio-immunotherapy of epidermal growth factor receptor-over expressing tumors. Cancer Biother Radiopharm 2011;26:287-97
   PubMed Web of Science ®Google Scholar
• Reddy BK, Vidyasagar MS, Koteshwar R, et al. A phase IIb 4-arm open-label randomized study to asses the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. J Clin Oncol 2009;27(15s Suppl):abstract 6041
   Google Scholar
• Lam C, Bouffet E, Bartels U. Nimotuzumab in pediatric glioma. Future Oncol 2009;5(9):1349-61
   PubMedGoogle Scholar
• Bebb G, Smith C, Rorke S, et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III, or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2011;67(4):837-45
   PubMed Web of Science ®Google Scholar
• Choi HJ, Sohn JH, Lee CG, et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIb-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer 2011;71(1):55-9
   PubMedGoogle Scholar
• Kumar P, Kanaka GB, Ashok K, et al. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: a phase II, open-label, multicenter, randomized study. J Clin Oncol 2013;31:abstract 8053
   Google Scholar
• De Haard HJ, Van Neer N, Reurs A, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999;274:18218-30
   PubMed Web of Science ®Google Scholar
• Lu D, Zhang H, Ludwig D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004;279:2856-65
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang H, Jimenez X, et al. Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy. AACR Meeting Abstracts 2004;64:163-c
   Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11
   PubMed Web of Science ®Google Scholar
• Shiqing LI, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008;16:216-27
   PubMedGoogle Scholar
• Stanfield RL, Zemla A, Wilson IA, Rupp B. Antibody elbow angles are influenced by their light chain class. J Mol Biol 2006;357:1566-74
   PubMed Web of Science ®Google Scholar
• Patel D, Saxena B, Zhou Q, et al. Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR- expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab. Proc Am Soc Clin Oncol 2011;29:abstract e21075
   Google Scholar
• Prewett M, Tonra JR, Rajiv B, et al. Antitumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human tumor xenograft models. Proc Am Assoc Cancer Res 2004;45:abstract 5353
   Google Scholar
• Prewett M, Tonra JR, Bassi R, et al. Anti-tumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC11F8) in human colon carcinoma xenograft models with enhanced activity in combination with CPT11. Eur J Cancer Suppl 2004;2:abstract 314
   Google Scholar
• Prewett M, Bassi R, Youssoufian H, et al. The fully Human EGFR antibody IMC-11F8 significantly increases the antitumor effects of cisplatin + gemcitabine in human non-small cell lung cancer models. PROC Am Assoc Cancer Res 2009;69:abstract 2774
   Google Scholar
• Kuenen B, Witteveen PO, Ruijter R, et al. A Phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010;16:1915-23
   PubMed Web of Science ®Google Scholar
• Study of IMC-11F8 in Patients With Advanced Solid Tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01088464
   Google Scholar
• A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC). Available from: https://clinicaltrials.gov/ct2/show/NCT01763788
   Google Scholar
• A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01769391
   Google Scholar
• A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin. Available from: https://clinicaltrials.gov/ct2/show/NCT01606748
   Google Scholar
• A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01788566
   Google Scholar
• A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01624467
   Google Scholar
• Tabernero J, Cervantes A, Delanoit T, et al. A phase 2 study of IMC-11F8 (necitumumab), a monoclonal antibody (mAb) directed against the epidermal growth factor receptor (EGFR), in combination with mFOLFOX6 chemotherapy in the first line treatment of advanced or metastatic colorectal carcinoma. ESMO 11th World Congress on Gastrointestinal Cancer; 2009. abstract 546
   Google Scholar
• Paz-Ares L, Mezger J, Ciulenau T, et al. Randomized phase-3 trial (INSPIRE) of necitumumab plus cisplatin-pemetrexed versus cisplatin-pemetrexed alone as first-line therapy in stage IV non-squamous NSCLC. Presented as an abstract and oral presentation at IASLC 15th World Conference on Lung Cancer; 2013. abstract 2337
   Google Scholar
• Thatcher N, Hirsh F, Luft AV, et al. SQUIRE: a randomized, multicenter, open-label, phase III trial study of gemcitabine-cisplatin (GEM-CIS) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GEM-CIS alone in the first line treatment of patients with stage IV squamous non-small cell lung cancer (sq-NSCLC). Presented as an abstract and oral presentation at the 50th Annual Meeting of the ASCO; 2014. abstract 8008
   Google Scholar
• O’Byrne K, Rodrigues Pereira J, von Pawel J, et al. Molecular and clinical biomarkers of outcome with cetuximab: data from the Phase III FLEX study in non-small cell lung cancer. Eur J Cancer 2009;7:553
   Google Scholar
• Mack PC, Gandara DR, Omori A, et al. KRAS mutation analysis in NSCLC versus colorectal cancer (CRC): implications for EGFR-directed therapies. IASLC Word Conference on Lung Cancer; San Francisco, CA; 2009
   Google Scholar
• Casaluce F, Sgambato A, Sacco PC, et al. Emerging drugs targeting PD-1 and PD-L1: reality or hopes? Expert Opin Emerg Drugs 2014;19(4):557-69
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Horn L, Gandhi L, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. J Clin Oncol 2014;32(5 Suppl):abstract 8112
   Google Scholar